Evidence map›Paper›PMID 24922153›Full record

ArticleAmerican journal of public health2014

Sources of racial/ethnic differences in awareness of HIV vaccine trials.

Michael P Arnold, Michele Andrasik, Stewart Landers, Shelly Karuna, Matthew J Mimiaga, Steven Wakefield, Kenneth Mayer, Susan Buchbinder, Beryl A Koblin

Abstract read
In one paragraph

Article in American journal of public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Building Trust and Engaging Communities for HIV Prevention Research Globally.AIDS education and prevention : official publication of the International Society for AIDS Education · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Michael P ArnoldMichael P. Arnold, Michele Andrasik, Shelly Karuna, and Steven Wakefield are with the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Stewart Landers is with Boston Health Services, John Snow Inc., Boston, MA. Matthew J. Mimiaga is with the Department of Epidemiology, Harvard School of Public Health, Cambridge, MA. Kenneth Mayer is with the Department of Global Health and Population, Harvard School of Public Health. Susan Buchbinder is with Bridge HIV, San Francisco Department of Public Health, San Francisco, CA. Beryl A. Koblin is with Project Achieve, New York Blood Center, New York, NY.
Michele Andrasik
Stewart Landers
Shelly Karuna
Matthew J Mimiaga
Steven Wakefield
Kenneth Mayer
Susan Buchbinder
Beryl A Koblin
Massachusetts Department of Public Health · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
Leadership Group for a Global HIV Vaccine Clinical Trials NetworkU01AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COREY, LAWRENCE · 2006 to 2010
$181.5M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
NIAID NIH HHS 3U01AI068614-04S1NIAID NIH HHS U01 AI068614NIAID NIH HHS UM1 AI068614NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

objectivesWe explored the relative effects of 2 awareness components-exposure and attention-on racial/ethnic differences in HIV vaccine trial awareness among men who have sex with men (MSM).

methodsSurveys assessing awareness of and attitudes toward HIV vaccine trials were administered to 1723 MSM in 6 US cities. Proxy measures of exposure included use of HIV resources and other health care services, community involvement, income, and residence. Attention proxy measures included research attitudes, HIV susceptibility, and HIV message fatigue. Using logistic regression models, we assessed the extent to which these proxies accounted for racial/ethnic differences in vaccine trial awareness.

resultsWhite MSM reported significantly (P < .01) higher rates of HIV vaccine trial awareness (22%) compared with Latino (17%), Black (13%) and "other" (13%) MSM. Venue-based exposure proxies and research-directed attitudinal attention proxies were significantly associated with awareness, but only accounted for the White-Latino disparity in awareness. No proxies accounted for the White-Black or White-"other" differentials in awareness.

conclusionsSources of disparities in awareness of HIV vaccine trials remain to be explained. Future trials seeking to promote diverse participation should explore additional exposure and attention mediators.

Indexed as

Health Knowledge, Attitudes, PracticeAdolescentAdultAIDS VaccinesAttitude to HealthBlack or African AmericanBlack PeopleClinical Trials as TopicEthnicityHispanic or LatinoHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedRacial GroupsAIDS Vaccines

Identifiers

PMID24922153
PMCPMC4103242
OpenAlexW2169061183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.